MDC Connects Series 2021 | A Guide to Complex Medicines: The Early Assessment of Prototype Nanomedicine Nano Bio Interactions - Zahra Rattray (University of Strathclyde)
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck gives an overview of the early assessment of Prototype Nanomedicine Nano Bio Interactions.
Zahra Rattray, University of Strathclyde
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at CryoEM in characterisation and quality control of complex medicines
Dr Rebecca Thompson, Astbury Biostructure Laboratory
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at cellular internalisation and trafficking of complex medicines.
Dr Jamie Szczerkowski, Medicines Discovery Catapult
This document discusses strategies for demonstrating target engagement in cellular assays. It notes that lack of efficacy is a major cause of drug failure and that showing target engagement can improve success. The document outlines various approaches for assessing if a compound reaches its target and engages with it in a cellular environment, including biochemical assays, cellular thermal shift assays, bioluminescence resonance energy transfer, and examining downstream markers. The goal is to validate that leads are engaging their intended target and modulating the disease pathway.
This document discusses biomarkers for assessing immune function throughout the drug development process. It describes how various techniques can be used to identify, validate, and qualify biomarkers. These include flow cytometry to analyze cell populations and activation markers, Luminex to measure cytokine levels, and gene expression profiling using NanoString. Whole blood stimulation assays are discussed as a way to assess target engagement and immune responses ex vivo. The importance of assay validation and understanding sources of variation are also covered. Biomarkers can provide insights into mechanisms of action, safety, and efficacy to support clinical development.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
This document discusses using preclinical models to demonstrate proof of concept efficacy for new cancer therapies. It outlines services available from Alderley Oncology including efficacy, pharmacokinetic and biomarker studies using mouse xenograft and syngeneic models. Case studies are presented on an FGFR inhibitor and PI3K inhibitor, showing how the right preclinical models helped validate mechanisms of action and identify patient populations most likely to respond. Successful preclinical studies for the FGFR inhibitor led to ongoing clinical trials in lung cancer. Exploring the PI3K inhibitor in syngeneic models revealed a novel immune-mediated mechanism of action.
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at CryoEM in characterisation and quality control of complex medicines
Dr Rebecca Thompson, Astbury Biostructure Laboratory
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at how you can determine efficacy in vivo.
Jenny Worthington (Axis Bio)
Our fifth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at physicochemical characterisation new and novel approaches to understand the pharmacokinetics of complex drugs.
Juliana Maynard (MDC)
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at cellular internalisation and trafficking of complex medicines.
Dr Jamie Szczerkowski, Medicines Discovery Catapult
This document discusses strategies for demonstrating target engagement in cellular assays. It notes that lack of efficacy is a major cause of drug failure and that showing target engagement can improve success. The document outlines various approaches for assessing if a compound reaches its target and engages with it in a cellular environment, including biochemical assays, cellular thermal shift assays, bioluminescence resonance energy transfer, and examining downstream markers. The goal is to validate that leads are engaging their intended target and modulating the disease pathway.
This document discusses biomarkers for assessing immune function throughout the drug development process. It describes how various techniques can be used to identify, validate, and qualify biomarkers. These include flow cytometry to analyze cell populations and activation markers, Luminex to measure cytokine levels, and gene expression profiling using NanoString. Whole blood stimulation assays are discussed as a way to assess target engagement and immune responses ex vivo. The importance of assay validation and understanding sources of variation are also covered. Biomarkers can provide insights into mechanisms of action, safety, and efficacy to support clinical development.
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the target landscape for Complex Medicine.
Dr Duygu Yilmaz, Medicines Discovery Catapult
This document discusses using preclinical models to demonstrate proof of concept efficacy for new cancer therapies. It outlines services available from Alderley Oncology including efficacy, pharmacokinetic and biomarker studies using mouse xenograft and syngeneic models. Case studies are presented on an FGFR inhibitor and PI3K inhibitor, showing how the right preclinical models helped validate mechanisms of action and identify patient populations most likely to respond. Successful preclinical studies for the FGFR inhibitor led to ongoing clinical trials in lung cancer. Exploring the PI3K inhibitor in syngeneic models revealed a novel immune-mediated mechanism of action.
This document discusses the advantages of using primary cellular models in drug development. Primary cells better mimic native biology and target expression compared to cell lines. Several case studies are presented where primary cellular models helped validate drug targets and identify potential safety issues prior to clinical trials. The document emphasizes characterizing fit-for-purpose models to generate relevant data at each stage of development from discovery to clinical translation. Thorough assay development and validation are important to support clinical applications.
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
Aurelia Bioscience is a biology CRO that offers various assay development and screening services including:
- NanoBRET assays to study protein-protein interactions and target engagement of kinases
- High throughput screening of over 50,000 compounds using their NanoBRET assays which identified hit compounds
- Target engagement assays using NanoBRET technology to study binding kinetics and residency times of compounds in living cells
- PROTAC drug discovery services using their degradation technology
- High throughput western blotting using the Protein Simple WES system
- Future plans to develop 3D cell-based assays using electrospun scaffold materials.
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
The document discusses targeted libraries for hit identification in drug discovery. It describes how targeted libraries can exploit target knowledge to identify hits through smaller, faster, and less expensive screens compared to high-throughput screening. Targeted libraries can be designed based on the biological target, location such as for central nervous system targets, or mechanism of action. The document provides examples of approaches for selecting compounds for targeted libraries, including using scaffolds associated with bioactivity, machine learning models trained on active and inactive compounds, and physicochemical properties or pharmacophores to allow for diversity. It emphasizes starting with developable molecules and avoiding frequent hitters or those with undesirable mechanisms.
The document discusses optimizing ADME and PK properties in drug development. It addresses common mistakes such as believing that intrinsic clearance cannot be optimized or that increasing plasma protein binding will always benefit PK. It emphasizes that intrinsic clearance, uptake clearance, and renal clearance all contribute to in vivo clearance. Good quality experimental data is important for accurate prediction of human PK. Formulation strategies can improve bioavailability when absorption is limited, but not if clearance is the dominant elimination pathway. The effects of plasma protein binding on free drug exposure are also explained.
Domainex is a contract research organization located in Cambridge, UK that provides integrated drug discovery services including medicinal chemistry, protein production and biophysics, and screening. They have experience working with many of the top pharmaceutical companies and have produced over 60 patents and 100 scientific papers. Domainex utilizes a comprehensive approach involving multiple disciplines to identify hits against drug targets. As a case study, they used fragment-based screening and x-ray crystallography to identify small molecule fragments that bind the epigenetic target G9a, which they then expanded into lead compounds.
This lecture outlines the different strategies for finding a fragment hit and the subsequent elaboration strategies used in order to increase potency to develop a lead compound in drug discovery.
This document discusses genomics and proteomics based drug discovery. It explains that genomics involves sequencing genomes to understand gene functions and interactions, while proteomics studies protein expression and interactions. The document outlines how structural bioinformatics and techniques like protein-ligand docking can help in drug target identification and rational drug design. It also discusses how proteomics can aid in various stages of drug discovery like target identification and validation.
The Proteomics and Metabolomics Shared Resource (PMSR) at Georgetown University provides proteomics and metabolomics services and expertise. The document describes the PMSR's integrated proteomics workflow including 2D gel-based analysis, DIGE, spot picking, and MALDI TOF/TOF mass spectrometry for protein identification. Liquid chromatography-based proteomics using iTRAQ/ICAT labeling for quantitative analysis and a nano LC-QSTAR ELITE mass spectrometer are also described. The PMSR supports small molecule profiling and quantitation using UPLC-TOFMS and metabolomics applications.
Applications of Genomic and Proteomic ToolsRaju Paudel
This document provides an overview of genomic and proteomic tools. It discusses topics like genomics, which is the study of genomes including structural and functional genomics. Proteomics is defined as the large-scale study of proteins, their structures and functions. Several techniques are described briefly, including DNA gel electrophoresis, polymerase chain reaction (PCR), real-time PCR, DNA sequencing, microarray technology, enzyme-linked immunosorbent assay (ELISA), and blotting techniques like Southern blotting, Northern blotting and Western blotting. Applications of these various tools are also mentioned.
This document discusses protein production and structure determination. It covers expressing recombinant proteins in common systems like E. coli, insect, and mammalian cells. Purification methods like affinity and size-exclusion chromatography are described. Quality control steps involving SDS-PAGE, mass spectrometry, and functional assays are outlined. Protein crystallography and X-ray crystal structure determination are summarized, including crystallization screening, diffraction data collection, phasing methods, and model building and refinement. The importance of protein structures for drug design is also briefly mentioned.
This document discusses the application of clinical proteomics in disease diagnosis and biomarker discovery. It provides an overview of how proteomics methodologies like mass spectrometry and protein microarrays can be used to identify protein biomarkers for various diseases from body fluids. Specific examples are given of proteomics studies that have discovered protein biomarker patterns or specific proteins that can improve diagnosis of cancers like colorectal cancer and breast cancer compared to single biomarkers. Biomarkers identified for other diseases like Alzheimer's disease and diabetic nephropathy through proteomics are also summarized.
Bioinformatics is an interdisciplinary field that combines biology, computer science, and information technology. It enables the discovery of new biological insights and unifying principles in biology through the merging of these disciplines. There are three main sub-disciplines: developing algorithms and statistics for analyzing large datasets, analyzing various types of biological data like sequences and structures, and developing tools for accessing and managing information.
Role of nuclicacid microarray &protein micro array for drug discovery processmohamed abusalih
role of nuclic acid microarray and protein microarray for drug discovery process
1.introduction about microarray technique and genomics
2.process of drug discovery
3.microarray techiques
4.microarray analysis in drug discovery
5.steps involved in the micro array analysis
Cell based assays presentation V2_03_2012Pete Shuster
This document provides an executive overview of a company called Neuromics/Vitro Biopharma that develops pre-clinical tools for drug discovery using human stem cell-derived cell systems. The company offers physiologically relevant human cells and cellular systems to enable better in vitro screening and target identification, reducing animal models and shortening development timelines. Key offerings include human stem cell-derived neuronal cells, glial cells, immune cells and other cell types, specialized media, transfection reagents, markers and labeling technologies. The company aims to improve early drug discovery through more predictive human cell-based assays.
The document discusses various drug delivery methods including conventional methods like oral, injection, and transdermal delivery as well as novel methods like liposomes, peptides, nanoparticles, and nanocomposites. Liposomes are described as tiny bubbles enclosed by a phospholipid bilayer that can encapsulate drug molecules and target delivery to specific tissues. Peptide drug delivery uses short chains of amino acids linked by peptide bonds to deliver drugs. Nanocomposites embed nano-sized particles in a polymer matrix, exhibiting enhanced properties while reducing cytotoxicity. Novel drug delivery provides benefits over conventional methods like reduced side effects, targeted delivery, and controlled release of drugs.
Genomics and proteomics in drug discovery and developmentSuchittaU
This document discusses the role of genomics and proteomics in drug discovery and development. It explains that genomics and proteomics technologies can help identify new drug targets by comparing gene and protein expression between healthy and diseased cells. Proteomics in particular analyzes changes in protein levels and can quantify individual proteins using techniques like 2D gel electrophoresis and mass spectrometry. The integration of genomics and proteomics provides a more comprehensive understanding of biological systems and is improving the drug discovery process.
This document discusses the role and methods of systems biology in drug discovery and development. It covers key topics such as:
- The challenges of interpreting large omics data sets and how systems biology aims to integrate multi-omics data.
- Examples of how systems biology approaches like computational modeling can be used in target discovery, understanding drug mechanisms of action, predicting drug combinations, and more.
- How systems biology methods that combine experimental data with modeling are being applied across various stages of the drug development process from preclinical research to determining side effects.
Immunoglobulins or antibodies can be used as targeted drug delivery systems by conjugating drugs or drug-activating enzymes to antibodies. This allows the drug or enzyme to be delivered specifically to cells that express the antigen targeted by the antibody. Some advantages are lower drug doses needed, fewer side effects, and better penetration of tissues. Applications discussed include PEG-immunoliposomes, ATTEMPTS which uses an antibody-heparin-drug complex, polymerizable antibody fragments, immunoconjugates, and ADEPT which uses an antibody-enzyme conjugate to activate a prodrug at tumor sites.
The document discusses protein-protein interactions (PPIs), including an introduction to PPIs, the types of interactions, techniques used to study them like X-ray crystallography, NMR spectroscopy and cryo-electron microscopy, and factors that affect PPIs. It also covers methods to investigate PPIs such as affinity purification coupled with mass spectrometry and yeast two-hybrid screening. Applications of understanding PPIs include developing therapeutic drugs and identifying functions of unknown proteins.
1. This study explored the molecular mechanisms of drought tolerance in ryegrass varieties by integrating transcriptomics, proteomics, and metabolomics approaches.
2. The study identified differentially expressed metabolites, proteins, and transcripts in response to drought stress between a drought-resistant and susceptible ryegrass variety.
3. Methods included transcriptome sequencing, qRT-PCR, mass spectrometry, gas chromatography–mass spectrometry to analyze changes at the transcript, protein, and metabolite levels under drought conditions between the two varieties. This integrative omics analysis provided insights into drought tolerance mechanisms.
This document discusses the advantages of using primary cellular models in drug development. Primary cells better mimic native biology and target expression compared to cell lines. Several case studies are presented where primary cellular models helped validate drug targets and identify potential safety issues prior to clinical trials. The document emphasizes characterizing fit-for-purpose models to generate relevant data at each stage of development from discovery to clinical translation. Thorough assay development and validation are important to support clinical applications.
Our second webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at developing the assay cascade for complex medicines.
Tilly Bingham, Concept Life Sciences
Aurelia Bioscience is a biology CRO that offers various assay development and screening services including:
- NanoBRET assays to study protein-protein interactions and target engagement of kinases
- High throughput screening of over 50,000 compounds using their NanoBRET assays which identified hit compounds
- Target engagement assays using NanoBRET technology to study binding kinetics and residency times of compounds in living cells
- PROTAC drug discovery services using their degradation technology
- High throughput western blotting using the Protein Simple WES system
- Future plans to develop 3D cell-based assays using electrospun scaffold materials.
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at precision drug delivery with therapeutic microbubbles and the promise that they bring.
Louise Coletta, University of Leeds
The document discusses targeted libraries for hit identification in drug discovery. It describes how targeted libraries can exploit target knowledge to identify hits through smaller, faster, and less expensive screens compared to high-throughput screening. Targeted libraries can be designed based on the biological target, location such as for central nervous system targets, or mechanism of action. The document provides examples of approaches for selecting compounds for targeted libraries, including using scaffolds associated with bioactivity, machine learning models trained on active and inactive compounds, and physicochemical properties or pharmacophores to allow for diversity. It emphasizes starting with developable molecules and avoiding frequent hitters or those with undesirable mechanisms.
The document discusses optimizing ADME and PK properties in drug development. It addresses common mistakes such as believing that intrinsic clearance cannot be optimized or that increasing plasma protein binding will always benefit PK. It emphasizes that intrinsic clearance, uptake clearance, and renal clearance all contribute to in vivo clearance. Good quality experimental data is important for accurate prediction of human PK. Formulation strategies can improve bioavailability when absorption is limited, but not if clearance is the dominant elimination pathway. The effects of plasma protein binding on free drug exposure are also explained.
Domainex is a contract research organization located in Cambridge, UK that provides integrated drug discovery services including medicinal chemistry, protein production and biophysics, and screening. They have experience working with many of the top pharmaceutical companies and have produced over 60 patents and 100 scientific papers. Domainex utilizes a comprehensive approach involving multiple disciplines to identify hits against drug targets. As a case study, they used fragment-based screening and x-ray crystallography to identify small molecule fragments that bind the epigenetic target G9a, which they then expanded into lead compounds.
This lecture outlines the different strategies for finding a fragment hit and the subsequent elaboration strategies used in order to increase potency to develop a lead compound in drug discovery.
This document discusses genomics and proteomics based drug discovery. It explains that genomics involves sequencing genomes to understand gene functions and interactions, while proteomics studies protein expression and interactions. The document outlines how structural bioinformatics and techniques like protein-ligand docking can help in drug target identification and rational drug design. It also discusses how proteomics can aid in various stages of drug discovery like target identification and validation.
The Proteomics and Metabolomics Shared Resource (PMSR) at Georgetown University provides proteomics and metabolomics services and expertise. The document describes the PMSR's integrated proteomics workflow including 2D gel-based analysis, DIGE, spot picking, and MALDI TOF/TOF mass spectrometry for protein identification. Liquid chromatography-based proteomics using iTRAQ/ICAT labeling for quantitative analysis and a nano LC-QSTAR ELITE mass spectrometer are also described. The PMSR supports small molecule profiling and quantitation using UPLC-TOFMS and metabolomics applications.
Applications of Genomic and Proteomic ToolsRaju Paudel
This document provides an overview of genomic and proteomic tools. It discusses topics like genomics, which is the study of genomes including structural and functional genomics. Proteomics is defined as the large-scale study of proteins, their structures and functions. Several techniques are described briefly, including DNA gel electrophoresis, polymerase chain reaction (PCR), real-time PCR, DNA sequencing, microarray technology, enzyme-linked immunosorbent assay (ELISA), and blotting techniques like Southern blotting, Northern blotting and Western blotting. Applications of these various tools are also mentioned.
This document discusses protein production and structure determination. It covers expressing recombinant proteins in common systems like E. coli, insect, and mammalian cells. Purification methods like affinity and size-exclusion chromatography are described. Quality control steps involving SDS-PAGE, mass spectrometry, and functional assays are outlined. Protein crystallography and X-ray crystal structure determination are summarized, including crystallization screening, diffraction data collection, phasing methods, and model building and refinement. The importance of protein structures for drug design is also briefly mentioned.
This document discusses the application of clinical proteomics in disease diagnosis and biomarker discovery. It provides an overview of how proteomics methodologies like mass spectrometry and protein microarrays can be used to identify protein biomarkers for various diseases from body fluids. Specific examples are given of proteomics studies that have discovered protein biomarker patterns or specific proteins that can improve diagnosis of cancers like colorectal cancer and breast cancer compared to single biomarkers. Biomarkers identified for other diseases like Alzheimer's disease and diabetic nephropathy through proteomics are also summarized.
Bioinformatics is an interdisciplinary field that combines biology, computer science, and information technology. It enables the discovery of new biological insights and unifying principles in biology through the merging of these disciplines. There are three main sub-disciplines: developing algorithms and statistics for analyzing large datasets, analyzing various types of biological data like sequences and structures, and developing tools for accessing and managing information.
Role of nuclicacid microarray &protein micro array for drug discovery processmohamed abusalih
role of nuclic acid microarray and protein microarray for drug discovery process
1.introduction about microarray technique and genomics
2.process of drug discovery
3.microarray techiques
4.microarray analysis in drug discovery
5.steps involved in the micro array analysis
Cell based assays presentation V2_03_2012Pete Shuster
This document provides an executive overview of a company called Neuromics/Vitro Biopharma that develops pre-clinical tools for drug discovery using human stem cell-derived cell systems. The company offers physiologically relevant human cells and cellular systems to enable better in vitro screening and target identification, reducing animal models and shortening development timelines. Key offerings include human stem cell-derived neuronal cells, glial cells, immune cells and other cell types, specialized media, transfection reagents, markers and labeling technologies. The company aims to improve early drug discovery through more predictive human cell-based assays.
The document discusses various drug delivery methods including conventional methods like oral, injection, and transdermal delivery as well as novel methods like liposomes, peptides, nanoparticles, and nanocomposites. Liposomes are described as tiny bubbles enclosed by a phospholipid bilayer that can encapsulate drug molecules and target delivery to specific tissues. Peptide drug delivery uses short chains of amino acids linked by peptide bonds to deliver drugs. Nanocomposites embed nano-sized particles in a polymer matrix, exhibiting enhanced properties while reducing cytotoxicity. Novel drug delivery provides benefits over conventional methods like reduced side effects, targeted delivery, and controlled release of drugs.
Genomics and proteomics in drug discovery and developmentSuchittaU
This document discusses the role of genomics and proteomics in drug discovery and development. It explains that genomics and proteomics technologies can help identify new drug targets by comparing gene and protein expression between healthy and diseased cells. Proteomics in particular analyzes changes in protein levels and can quantify individual proteins using techniques like 2D gel electrophoresis and mass spectrometry. The integration of genomics and proteomics provides a more comprehensive understanding of biological systems and is improving the drug discovery process.
This document discusses the role and methods of systems biology in drug discovery and development. It covers key topics such as:
- The challenges of interpreting large omics data sets and how systems biology aims to integrate multi-omics data.
- Examples of how systems biology approaches like computational modeling can be used in target discovery, understanding drug mechanisms of action, predicting drug combinations, and more.
- How systems biology methods that combine experimental data with modeling are being applied across various stages of the drug development process from preclinical research to determining side effects.
Immunoglobulins or antibodies can be used as targeted drug delivery systems by conjugating drugs or drug-activating enzymes to antibodies. This allows the drug or enzyme to be delivered specifically to cells that express the antigen targeted by the antibody. Some advantages are lower drug doses needed, fewer side effects, and better penetration of tissues. Applications discussed include PEG-immunoliposomes, ATTEMPTS which uses an antibody-heparin-drug complex, polymerizable antibody fragments, immunoconjugates, and ADEPT which uses an antibody-enzyme conjugate to activate a prodrug at tumor sites.
Similar to MDC Connects Series 2021 | A Guide to Complex Medicines: The Early Assessment of Prototype Nanomedicine Nano Bio Interactions - Zahra Rattray (University of Strathclyde)
The document discusses protein-protein interactions (PPIs), including an introduction to PPIs, the types of interactions, techniques used to study them like X-ray crystallography, NMR spectroscopy and cryo-electron microscopy, and factors that affect PPIs. It also covers methods to investigate PPIs such as affinity purification coupled with mass spectrometry and yeast two-hybrid screening. Applications of understanding PPIs include developing therapeutic drugs and identifying functions of unknown proteins.
1. This study explored the molecular mechanisms of drought tolerance in ryegrass varieties by integrating transcriptomics, proteomics, and metabolomics approaches.
2. The study identified differentially expressed metabolites, proteins, and transcripts in response to drought stress between a drought-resistant and susceptible ryegrass variety.
3. Methods included transcriptome sequencing, qRT-PCR, mass spectrometry, gas chromatography–mass spectrometry to analyze changes at the transcript, protein, and metabolite levels under drought conditions between the two varieties. This integrative omics analysis provided insights into drought tolerance mechanisms.
Structural genomics aims to determine the 3D structures of all proteins encoded by genomes through high-throughput methods. It uses a genome-based approach to solve protein structures rapidly and cost-effectively. Major initiatives like the Protein Structure Initiative have made progress in determining thousands of protein structures. Challenges include expressing membrane and eukaryotic proteins, as well as determining remaining novel folds. Determining protein structures through structural genomics increases understanding of protein function and facilitates drug discovery.
Proteomics in VSC for crop improvement programmeSumanthBT1
Proteomics techniques such as gel electrophoresis and mass spectrometry are used to separate and identify proteins. Two-dimensional gel electrophoresis separates proteins by size and charge, while MALDI-TOF mass spectrometry relies on mass spectrometry to analyze proteins and peptides. Protein-protein interactions can be studied using techniques like yeast two-hybrid systems and co-immunoprecipitation. Databases such as UniProt, PDB, and KEGG provide information on protein sequences, structures, and pathways.
This study performed a comparative metagenomic analysis of fecal samples from 13 healthy individuals of various ages to identify genomic features common and variable among human gut microbiomes. It found that gut microbiomes from unweaned infants were simple and highly variable, while adults and weaned children were more complex but functionally uniform. 237 gene families were commonly enriched in adult microbiomes and 136 in infant microbiomes, with a small overlap. 647 new gene families were exclusively present in human intestinal microbiomes.
In vitro studies are experiments conducted using isolated cells, biological molecules, or tissues that have been removed from their usual biological context. These "test tube experiments" allow for a more detailed analysis than can be done with whole living organisms. Some key advantages of in vitro studies are their simplicity, ability to study human cells directly, and potential for high-throughput screening. However, results must be carefully extrapolated to make predictions about living organisms, as cellular responses in vitro do not always translate to whole body responses in vivo. Mathematical modeling is often used to bridge this gap between in vitro and in vivo data.
This document discusses various biochemical analysis techniques used to analyze biomolecules like proteins, lipids, and drugs. It provides details on techniques like chromatography, electrophoresis, centrifugation, and spectroscopy. It also describes specific applications of these techniques like analyzing phospholipase D and determining the amino acid composition of proteins.
This document discusses various bioinformatics approaches for analyzing molecular interactions, including protein-protein interaction, protein-ligand interaction, docking, pharmacophore, and virtual screening. It provides details on each topic, describing things like how protein-protein interactions occur and are classified, common methods for studying protein-ligand interactions, the basic process and types of docking, and the definition of a pharmacophore. The key topics covered are protein-protein interaction, protein-ligand interaction analysis through methods like docking, and virtual screening using pharmacophore models.
Proteomics, definatio , general concept, signficanceKAUSHAL SAHU
INTRODUCTION
GENERAL CONCEPT
WHY PROTEIOMIC NECESERY?
WHAT PROTEOMIC CAN ANSWER?
PRTEOMICS- ANALYSIS AND IDENTIFICATION OF PROTEIN
TWO-DIMENSIONAL SDS-PAGE
MASS SPECTROMETERS
SIGNIFICANCE OF STUDY AN ITS IMPORTANCE
APPLICATIONS
CHALLENGES
CONCLUSIONS
REFERENCES
Proteomics and its applications in phytopathologyAbhijeet Kashyap
Dear friends, I Abhijeet kashyap presenting the basics of proteomics to you all . Proteomics is the large-scale study of proteins, particularly their structures and functions.Proteomics helps in understanding the structure and function of different proteins as well as protein-protein interactions of an organism.
Bioengineered 3D Co culture Lung In Vitro Models: Platforms to Integrate Cell...Ken Rogan
Cian O'Leary and his lab are developing 3D bioengineered in vitro models of the lung and other tissues using scaffolds.
[1] They have created bilayered collagen-hyaluronate scaffolds that support a mucociliary epithelial phenotype in lung cell culture models.
[2] The lab is also working on 3D hydrogel models of pancreatic cancer to study cell-matrix interactions and cancer progression.
[3] Future work includes developing dynamically stiffening hydrogel models and applying these platforms to study lung cancer and the pre-metastatic niche.
1) Structure based drug design involves identifying drug candidates that bind to biological targets through techniques like molecular docking.
2) Docking attempts to predict how drug molecules bind to protein targets by finding low energy conformations when the drug and protein interact.
3) The process involves preparing the protein and drug molecules, defining the binding site, and using software to dock different conformations of the drug to identify favorable binding poses and affinity scores.
This document discusses systems pharmacology and applying a systems-based approach to understanding drug action and effects. It begins by outlining some big questions in pharmacology research, such as predicting drug efficacy and toxicity. It then discusses concepts like polypharmacology, where one drug can have multiple targets, and how drug binding is a dynamic process. The document proposes using multiscale modeling to simulate these complex biological processes. It describes developing computational methods to explore the large conformational and functional spaces involved. Several applications of these approaches are mentioned, such as drug repositioning and designing personalized medicines. Overall, the document advocates applying systems-level modeling and simulations to better understand how drugs work in the body.
Microorganisms such as bacteria, actinomycetes, and fungi are ubiquitous on our planet. They are widely distributed in soil, water, the human body and other environments. Microorganisms and their activities are of great importance to biogeochemical cycles and to all biological systems. Creative Proteomics provides a one-stop proteomics service from sample collection, protein separation, to protein quantification and bioinformatics analysis. We offer both relative quantification (including iTRAQ, TMT and SILAC) and absolute quantification (such as SRM/MRM and PRM) approaches to help you discover, detect and quantify proteins in a broad array of samples. https://www.creative-proteomics.com/services/proteomics-service.htm
Microorganisms such as bacteria, actinomycetes, and fungi are ubiquitous on our planet. They are widely distributed in soil, water, the human body and other environments. Microorganisms and their activities are of great importance to biogeochemical cycles and to all biological systems. Creative Proteomics provides a one-stop proteomics service from sample collection, protein separation, to protein quantification and bioinformatics analysis. We offer both relative quantification (including iTRAQ, TMT and SILAC) and absolute quantification (such as SRM/MRM and PRM) approaches to help you discover, detect and quantify proteins in a broad array of samples. https://www.creative-proteomics.com/services/proteomics-service.htm
This document provides information on genomics, proteomics, and metabolomics. It discusses that genomics is the study of genomes through sequencing and analysis. It involves various types of genomics like structural, functional, and comparative genomics. Proteomics is the large-scale study of the structure and function of proteins in organisms. Key proteomics methods include antibody detection and mass spectrometry. Metabolomics is the study of small molecule metabolites within cells and biofluids, which make up the metabolome. These "omics" fields provide insights into cellular processes and are applied in areas like disease diagnosis and drug development.
Proteomics is the study of the proteome, which is the complete set of proteins expressed by a genome or cell. It uses technologies like mass spectrometry and genetic analysis to study protein activities, modifications, localization, and interactions. Proteomic techniques can identify disease-related proteins and biomarkers for diagnosis before clinical symptoms appear. Two key proteomic techniques are gel electrophoresis, which separates proteins by charge and size, and mass spectrometry, which identifies proteins with high accuracy. Proteomics has applications in disease diagnosis, structural analysis, and functional studies of protein networks.
This document discusses how normalization methods for gene expression measurements that assume equal cellular RNA content across experimental conditions can mask differences in total RNA yield per cell. The authors demonstrate that total RNA yield from Chinese Hamster Ovary (CHO) cells varies between experimental treatments and cell lines expressing recombinant proteins. They apply a normalization method using synthetic spike-in RNA standards added proportionally to cell number, which reveals differences in cellular RNA content and allows detection of global transcriptional amplification or repression. They use this method to assess gene expression in CHO cell lines of different sizes treated with cell cycle or mTOR inhibitors, or subjected to high osmolarity conditions. They find that a cell cycle inhibitor increases cell size and transcriptional amplification, an mTOR inhibitor causes
Introduction to proteomics, techniques to study proteomics such as protein electrophoresis, chromatography and mass spectrometry and protein database analysis, case studies derived from scientific literature including comparisons between healthy and diseased tissues, new approaches to analyse metabolic pathways, comprehensive analysis of protein-protein interactions in different cell types.
Similar to MDC Connects Series 2021 | A Guide to Complex Medicines: The Early Assessment of Prototype Nanomedicine Nano Bio Interactions - Zahra Rattray (University of Strathclyde) (20)
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at overcoming the challenges of scaling up a complex medicine.
Graham Worrall and Emily Port, CPI
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development Services
This document discusses some of the safety challenges that may be presented by complex medicines compared to traditional small molecule drugs. It notes that complex medicines like monoclonal antibodies, antibody-drug conjugates, and targeted protein degraders can pose different safety risks than small molecules related to their target, chemistry properties, and effects on patients. The document then provides three examples of complex medicine development programs to illustrate some of these safety considerations, such as enhancing drug penetration into tissues, characterizing the safety of combined drug-device products, and assessing the safety of approved drugs delivered in new ways.
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look Lipid Nanoparticles, and how there is so much more to them than being a little fat blob.
Yvonne Perrie (University of Strathclyde)
Our fourth webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at alternative delivery for mRNA vaccines.
Helen McCarthy, pHion Therapeutics
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the interaction of colloidal gene delivery vehicles with model biomembranes.
Jayne Lawrence, The University of Manchester
Our third webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the challenges of determining drug levels and pk profiles for complex drug modalities.
Robert Wheller, LGC
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the state of play for Complex Medicine and highlights the potential opportunity for the UK.
Prof Peter Simpson, Medicines Discovery Catapult
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
Small and medium enterprises (SMEs) need access to clinical samples for core research and development activities like progressing assets and launching new products, but there are several barriers that limit their access within UK biobanks. These barriers include biobanks not being adequately promoted, lack of awareness from researchers, no unified infrastructure, slow access committees and governance requirements. Overcoming these barriers will require action from regulatory bodies like the Health Research Authority and Human Tissue Authority, patient groups, and improvements to areas like cost recovery, customer awareness and management, operational processes, and documentation standardization by biobanks. Utilizing UK bioresources benefits long term sustainability and the UK economy.
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
This document discusses the opportunities and challenges of complex cell models for toxicity testing. It describes how next generation models using stem, primary and CRISPR edited cells in 3D organoids can better mimic the biological environment and improve translation to patients compared to traditional 2D single cell models. Specific complex cell models discussed include a 3D cardiac model using iPSC-derived cardiomyocytes, fibroblasts and endothelial cells to detect cardiotoxicity, as well as blood brain barrier and liver models. While these connected organ-on-chip models show potential, challenges remain around fully defining and validating the models, addressing missing organ systems and targets, achieving scalability and comparability, and demonstrating improved predictivity and translation to human outcomes.
This document discusses the importance of incorporating safety considerations into drug design from an early stage. It notes that safety issues related to the primary drug target remain a major reason for drug project failure and delay. Considering the target's normal physiological role allows researchers to anticipate and plan for potential toxicities. Early studies, such as in silico modeling, in vitro screening assays, and in vivo validations in animal models, can help identify potential safety hazards to hopefully design them out of drug candidates. Understanding toxicity risks in the context of the intended patient population can help assess the risk-benefit of a given drug target or compound series. Incorporating safety assessments from the beginning of the drug design process can lead to better informed decisions and improved chances of
This document discusses strategies for efficiently developing the non-clinical package needed to get a molecule into human trials. It outlines top reasons for delays like insufficient API, formulation issues, and unexpected toxicity. It recommends enhancing efficiency by selecting a CRO early, combining study endpoints, using biomarkers to inform clinical decisions, and microsampling to reduce animal numbers. Looking ahead, the future may see increased use of minipigs and humanized models with reduced primate use. Developing a defined strategy, partnership with an experienced CRO, and planning for unexpected events are crucial to improving efficiency.
1) Understanding the relationship between pharmacokinetics (PK) and pharmacodynamics (PD) through preclinical PKPD studies is important for determining effective drug doses and schedules.
2) Successful PKPD study design requires integrating knowledge across disciplines and testing a range of doses, time points, and biological parameters to understand target modulation and optimize efficacy while minimizing toxicity.
3) Case studies demonstrate how PKPD analysis of oncology and respiratory disease models identified optimal dosing schedules, with the oncology study changing from a daily high dose to thrice weekly lower doses to improve efficacy without toxicity.
Imaging can be used to evaluate pharmacodynamic endpoints in both preclinical and clinical studies. Preclinically, imaging such as PET can provide quantitative data on endpoints like tumor metabolism without invasive procedures. This can help reduce animal studies. Clinically, imaging biomarkers for conditions like osteoporosis, heart disease, and cancer provide anatomical and functional data on targets, proliferation, and hypoxia. Case studies demonstrate how imaging endpoints like tumor size and blood flow changes can support decision making in drug development from early research through approval. Imaging is positioned to continue advancing drug discovery by identifying new pharmacodynamic biomarkers.
This document discusses principles of pharmacokinetic (PK) and pharmacodynamic (PD) modeling. It notes that while all models are imperfect, some can still be useful. Simple models require fewer assumptions but more data, while complex models replace assumptions with data. The aim is the simplest useful model. Example models show how PK data can predict exposure from different doses and how PK-PD models integrate exposure over time with drug effects. Direct PK-PD models have effects directly linked to concentrations, while indirect models have time delays between exposure and response. Indirect models may allow less frequent dosing. The document stresses designing PK-PD studies based on all available knowledge to test hypotheses and obtain informative data on concentration-effect and time relationships
Dr. Alison Foster presented on designing formulations for pre-clinical and early stage clinical studies. Quay Pharmaceuticals is a contract development and manufacturing organization specializing in formulation of molecules. They focus on pre-clinical formulation to maximize dose and absorption in animal models and clinical formulation including pre-formulation, formulation development, and feasibility batches. Considerations for pre-clinical and clinical formulation include the active pharmaceutical ingredient properties, intended dosage form, and balancing risk, time, and cost based on the development strategy and goals.
1) Domainex used fragment-based drug discovery to develop DMXD-011, an inhibitor of IKKe and TBK1, as a potential treatment for interferonopathies like lupus. They started with a fragment hit that bound efficiently to IKKe and optimized it using structure-based drug design.
2) In collaboration with researchers, Domainex found that DMXD-011 dramatically reduced cytokine levels and interferon-stimulated gene expression in blood samples from patients with interferonopathies treated with an immune stimulant.
3) Domainex transformed an initial fragment hit into a drug candidate, DMXD-011, that shows promise as a treatment for auto
Authoring a personal GPT for your research and practice: How we created the Q...Leonel Morgado
Thematic analysis in qualitative research is a time-consuming and systematic task, typically done using teams. Team members must ground their activities on common understandings of the major concepts underlying the thematic analysis, and define criteria for its development. However, conceptual misunderstandings, equivocations, and lack of adherence to criteria are challenges to the quality and speed of this process. Given the distributed and uncertain nature of this process, we wondered if the tasks in thematic analysis could be supported by readily available artificial intelligence chatbots. Our early efforts point to potential benefits: not just saving time in the coding process but better adherence to criteria and grounding, by increasing triangulation between humans and artificial intelligence. This tutorial will provide a description and demonstration of the process we followed, as two academic researchers, to develop a custom ChatGPT to assist with qualitative coding in the thematic data analysis process of immersive learning accounts in a survey of the academic literature: QUAL-E Immersive Learning Thematic Analysis Helper. In the hands-on time, participants will try out QUAL-E and develop their ideas for their own qualitative coding ChatGPT. Participants that have the paid ChatGPT Plus subscription can create a draft of their assistants. The organizers will provide course materials and slide deck that participants will be able to utilize to continue development of their custom GPT. The paid subscription to ChatGPT Plus is not required to participate in this workshop, just for trying out personal GPTs during it.
Unlocking the mysteries of reproduction: Exploring fecundity and gonadosomati...AbdullaAlAsif1
The pygmy halfbeak Dermogenys colletei, is known for its viviparous nature, this presents an intriguing case of relatively low fecundity, raising questions about potential compensatory reproductive strategies employed by this species. Our study delves into the examination of fecundity and the Gonadosomatic Index (GSI) in the Pygmy Halfbeak, D. colletei (Meisner, 2001), an intriguing viviparous fish indigenous to Sarawak, Borneo. We hypothesize that the Pygmy halfbeak, D. colletei, may exhibit unique reproductive adaptations to offset its low fecundity, thus enhancing its survival and fitness. To address this, we conducted a comprehensive study utilizing 28 mature female specimens of D. colletei, carefully measuring fecundity and GSI to shed light on the reproductive adaptations of this species. Our findings reveal that D. colletei indeed exhibits low fecundity, with a mean of 16.76 ± 2.01, and a mean GSI of 12.83 ± 1.27, providing crucial insights into the reproductive mechanisms at play in this species. These results underscore the existence of unique reproductive strategies in D. colletei, enabling its adaptation and persistence in Borneo's diverse aquatic ecosystems, and call for further ecological research to elucidate these mechanisms. This study lends to a better understanding of viviparous fish in Borneo and contributes to the broader field of aquatic ecology, enhancing our knowledge of species adaptations to unique ecological challenges.
When I was asked to give a companion lecture in support of ‘The Philosophy of Science’ (https://shorturl.at/4pUXz) I decided not to walk through the detail of the many methodologies in order of use. Instead, I chose to employ a long standing, and ongoing, scientific development as an exemplar. And so, I chose the ever evolving story of Thermodynamics as a scientific investigation at its best.
Conducted over a period of >200 years, Thermodynamics R&D, and application, benefitted from the highest levels of professionalism, collaboration, and technical thoroughness. New layers of application, methodology, and practice were made possible by the progressive advance of technology. In turn, this has seen measurement and modelling accuracy continually improved at a micro and macro level.
Perhaps most importantly, Thermodynamics rapidly became a primary tool in the advance of applied science/engineering/technology, spanning micro-tech, to aerospace and cosmology. I can think of no better a story to illustrate the breadth of scientific methodologies and applications at their best.
Travis Hills' Endeavors in Minnesota: Fostering Environmental and Economic Pr...Travis Hills MN
Travis Hills of Minnesota developed a method to convert waste into high-value dry fertilizer, significantly enriching soil quality. By providing farmers with a valuable resource derived from waste, Travis Hills helps enhance farm profitability while promoting environmental stewardship. Travis Hills' sustainable practices lead to cost savings and increased revenue for farmers by improving resource efficiency and reducing waste.
The binding of cosmological structures by massless topological defectsSérgio Sacani
Assuming spherical symmetry and weak field, it is shown that if one solves the Poisson equation or the Einstein field
equations sourced by a topological defect, i.e. a singularity of a very specific form, the result is a localized gravitational
field capable of driving flat rotation (i.e. Keplerian circular orbits at a constant speed for all radii) of test masses on a thin
spherical shell without any underlying mass. Moreover, a large-scale structure which exploits this solution by assembling
concentrically a number of such topological defects can establish a flat stellar or galactic rotation curve, and can also deflect
light in the same manner as an equipotential (isothermal) sphere. Thus, the need for dark matter or modified gravity theory is
mitigated, at least in part.
The technology uses reclaimed CO₂ as the dyeing medium in a closed loop process. When pressurized, CO₂ becomes supercritical (SC-CO₂). In this state CO₂ has a very high solvent power, allowing the dye to dissolve easily.
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
MDC Connects Series 2021 | A Guide to Complex Medicines: The Early Assessment of Prototype Nanomedicine Nano Bio Interactions - Zahra Rattray (University of Strathclyde)
1. Dr Zahra Rattray
Chancellor’s Research Fellow
Laboratory of Complex Bioanalysis
MDC Connects Series 2021
May 2021
The Early Assessment of Prototype
Nanomedicine Nano-Bio Interactions
‘Where Nano meets Bio’
1
zahra.rattray@strath.ac.uk
2. The Biological Fate of Complex Medicines
2
Hard corona
Soft corona
Particle properties
Composition
Surface charge
Morphology
Size
Cargo
Concentration
…
Environmental parameters
Incubation media
Protein content and composition
Duration
Temperature
Flow rate
3. The Protein Corona: Why Measure the Protein Corona?
3
Impact on drug release
Colloidal Stability
Cellular Interactions
(cytotoxicity, immunotoxicity, uptake)
• Cellular uptake
• Complement activation
• Macrophage activation
• Circulation time
• Relative organ distribution
Organ Biodistribution
5. The Protein Corona Bioanalytical Toolbox- In vitro
5
Media Nanoparticle
Co-incubation
Nanoparticle isolation/recovery
(ex situ/in situ)
Corona proteins/pelleted particles
Separation
Digestion (peptide fragments)
Mass
Size,
Concentration,
Structural
Circular Dichroism/FTIR
Raman
NMR
Quantification
Protein assays
LC-MS/ICP-MS
Imaging TEM/cryo-TEM
Identification
MS
SDS-PAGE
ELISA
Affinity/Dynamics
ITC/QCM
Reported for metallic, inorganic, polymeric, etc
6. In situ Profiling of the Protein Corona- Physical Analysis
Daramy et al, Unpublished data- Laboratory of Complex Bioanalysis
Mean particle dry mass change relative to PLGA
nanoparticles treated in 10% FBS (n=3). * represents a
P<0.05, ** P<0.01, *** P<0.001. 6
Example- PLGA Nanoparticles
Resonant Mass Measurement PTA RMM
7. 7
The Protein Corona Bioanalytical Toolbox
Alberg, I., et al. (2020). Small 16(18): 1907574.
Weber, C., et al. (2018). Acta Biomaterialia 76: 217-224.
Weber, C., et al. (2019). Biomacromolecules 20(8): 2989-2999.
Field Flow Fractionation Doxorubicin liposomes in cell culture
media- EAF4 with light scattering
Other hyphenations of FFF exist!
Strathclyde Multiscale Metrology Facility (Q4 2021)
Field Flow Fractionation (asymmetric, electric and centrifugal) with
multiple light scattering, Raman and ICP-MS detection
Drexel et al. (2020). Molecules 25(20), 4703.
Asymmetric FFF
Centrifugal (CF3)
Electrical (EAF4)
SEC
8. 8
The Protein Corona Bioanalytical Toolbox- In vitro
Jayaram D.T., et al. (2018). Biophys J 114: 209-216.
Static versus flow conditions
Example- Polystyrene model nanoparticles (200 nm)
•Flow impacts corona composition
•Protein conformation changes between static vs flow
•Protein-dependent effects
•This effect has been observed with lipid nanoparticles
9. In the era of precision medicine …
• Microarray based assays for mimicking biorelevant conditions
• Multiplexing analytical measurements
• Multiscale models predicting and measuring the protein corona prototype
Line of Sight- The Precision Protein Corona Interactome
9
10. • Parallel physical and compositional assessment
• Biorelevant conditions
• In situ versus ex situ approaches
• Harmonization of reporting for biological interactions
• Interactome passport for each prototype!
• Combining in silico output with in vitro fingerprint
Summary
10
11. AstraZeneca
Past colleagues, too many to name!
Laboratory of the Government Chemist (LGC)
Dr Heidi Goenaga-Infante
Medicines Discovery Catapult
Dr Martin Main, Dr Graeme Wilkinson, Dr Duygu Yilmaz
Malvern Panalytical
Elise Guerini, Liam Cole
National Physical Laboratory
Caterina Minelli, Yiwen Pei
University of Strathclyde
Prof Duncan Graham (Pure & Applied Chemistry)
Prof Karen Faulds (Pure & Applied Chemistry)
Prof Yvonne Perrie (Pharmacy & Biomedical Sci)
Dr Nicholas Rattray (Pharmacy & Biomedical Sci)
Dr Asimina Kazakidi (Biomedical Engineering)
Prof Gavin Halbert (Pharmacy & Biomedical Sci)
Yale University
Dr James Hansen, Dr Caroline Johnson, Dr Jiangbing Zhou
Acknowledgments
Laboratory of Complex Bioanalysis
Miss Layla Alnoumas
Mr Abdullah Alsultan
Miss Zoe Apczynski
Mr Bhushan Bhale
Miss Domenica Berardi
Mr Karim Daramy
Mr Ahmed Gaafar
Ms Merrit Rothe
Mx Kiri Thornalley
11